Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological or cytological diagnosis of non-Hodgkin's lymphoma.~2. Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology examination or vitrectomy.~3. Disease exclusively localized into the central nervous system, cranial nerves or eyes.~4. Untreated patients (patients treated with steroids alone are eligible).~5. At least one measurable lesion.~6. Age 18 - 75 years.~7. ECOG performance status \< 3~8. HBsAg-negative and Ab anti-HCV-negative serologic status.~9. No known HIV disease or immunodeficiency.~10. Adequate bone marrow (PLT \> 100000 mm3, Hb ≥ 9 g/dl, ANC ≥ 2.000 mm3), renal (creatinine clearance ≥ 60 mL/min), cardiac (VEF ≥ 50%), and hepatic function (total serum bilirubin \< 3 mg/dL, AST/ALT and gGT \< 2 per upper normal limit value).~11. No previous or concurrent malignancies with the exception of surgically cured cervical intraepithelial neoplasia type 1 (CIN1) or localized non-melanomatous skin cancer and of other cancers without evidence of disease since at least 5 years (patients with a previous lymphoma diagnosis will be excluded).~12. Absence of any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.~13. Non-pregnant and non-lactating status for female patients. Adequate contraceptive measures during study participation for sexually active patients of childbearing potential.~14. No concurrent treatment with other experimental drugs.~15. Informed consent signed by the patient before registration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- High-dose methotrexate alone (Type: ACTIVE_COMPARATOR): None
- High-dose methotrexate associated with high dose cytarabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).